Oncothyreon, Inc. (NASDAQ: ONTY), a biotechnology company, is committed to the development of oncology products designed to improve the lives and outcomes of cancer patients. Currently, the company is in the process of developing multiple therapeutic candidates targeting cancer in specific and effective ways. With headquarters in Seattle, Washington, their pipeline includes both synthetic vaccines and small molecules for a variety of cancer indications. For further information, visit the Company’s web site at www.oncothyreon.com.
- 18 years ago
QualityStocks
Oncothyreon, Inc. (NASDAQ: ONTY)
Tags Rodman & Renshaw
Related Post
-
Quantum BioPharma Ltd. (NASDAQ: QNTM) Pursues a New Path for Better Multiple Sclerosis Treatments
In the United States alone, close to one million people are living with MS, with…
-
Why Verbal Skills Aren’t Enough: WRAP’s New Doctrine Aims to Give Officers a Lawful Next Step
California's SB 230 requires agencies to incorporate de-escalation and alternatives to force into their use-of-force…
-
Beeline Holdings Inc. (NASDAQ: BLNE) Partners with Loft 100 Studios to Examine the Mortgage Market and New Approaches to Homeownership
The partnership will focus on the production of a 45-minute “Bizumentary” examining current challenges and…